Samsung Epis Holdings Co, Ltd has officially been established as a new investment holding company, marking a significant step in the growth of Samsung Bioepis. The company will be listed on the Korea Exchange (KRX) on November 24, 2025, following the formation of a new subsidiary on November 14, 2025. Samsung Bioepis will remain a fully owned subsidiary of Samsung Epis Holdings, continuing to lead its biosimilar business.
Kyung-Ah Kim will serve as President and CEO of Samsung Epis Holdings, while also retaining her role as CEO of Samsung Bioepis. Kim commented, “Our new investment holding company is committed to uncovering investment opportunities in the biotechnology sector, driving the long-term growth of our subsidiaries. While continuing our commitment to biosimilars, we aim to expand into next-generation therapeutics and technologies.”
As a dedicated biopharmaceutical holding company, Samsung Epis Holdings will oversee strategic investments in biotechnology, aiming to create long-term value for both the company and its shareholders. The company will focus on advancing research and development (R&D) efforts and exploring new avenues for growth, particularly through its subsidiaries. This structure will provide more flexibility and independence for decision-making, enhancing Samsung Epis Holdings’ ability to pursue new opportunities in the biotech sector.
The new subsidiary under Samsung Epis Holdings will focus on developing cutting-edge biotechnology platforms. This company aims to identify and create innovative therapies, advancing scalable technologies into platforms that can discover and develop new drug candidates. Collaborative efforts with global pharmaceutical companies will also be key to driving innovation in this space.
Samsung Bioepis, which was founded in 2012, will continue to focus on its core mission of developing, manufacturing, and distributing high-quality biosimilars. The company’s portfolio has grown to 11 biosimilars that are approved and sold globally, and it achieved a record KRW 1.5377 trillion in sales and KRW 435.4 billion in operating profit in 2024. Moving forward, Samsung Bioepis aims to strengthen its R&D capabilities, with a goal of expanding its biosimilar portfolio to 20+ products in the long term. The company will also continue to expand its reach in immunology, oncology, ophthalmology, hematology, and nephrology, while exploring new therapeutic areas to meet patients’ unmet needs.
Kyung-Ah Kim concluded, “Through this new structure, we expect to accelerate innovation and position ourselves for sustainable growth in the rapidly evolving biotech landscape.” ChatGPT said:
Samsung Bioepis remains committed to its core operations—research and development, manufacturing, supply distribution, and commercialization of biologic medicines. Since its establishment in 2012, the company has built one of the fastest-growing biosimilar portfolios in the industry, with 11 biosimilars approved and nine currently available worldwide.
In 2024, Samsung Bioepis achieved record sales of KRW 1.5377 trillion and an operating profit of KRW 435.4 billion. Looking ahead, the company aims to enhance its development capabilities with the long-term goal of expanding its biosimilar portfolio to over 20 products. Having already improved access to biologic medicines across immunology, oncology, ophthalmology, hematology, and nephrology, Samsung Bioepis is now broadening its reach into additional therapeutic areas to meet the unmet needs of patients around the world.
